Search research articles
Contact Us
Filters
Showing results (221-230 of 437) with videos related to
Page
of 44
Sort By:
Clinical Lung Cancer
|
January 11, 2018
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results
Martin Reck, Edward B Garon, Luis Paz-Ares, et al.
Clinical Lung Cancer
|
May 26, 2022
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer
Salma K Jabbour, Byoung Chul Cho, Emilio Bria, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)
Rathi N Pillai, Suresh S Ramalingam, Meena Thayu, et al.
NPJ Precision Oncology
|
December 8, 2021
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
Arlou Kristina Angeles, Petros Christopoulos, Zhao Yuan, et al.
Drug Safety
|
December 20, 2021
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
Ernest Nadal, Hidehito Horinouchi, Jin-Yuan Shih, et al.
Future Oncology (London, England)
|
December 14, 2023
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced <i>EGFR</i>-mutated NSCLC after a third-generation EGFR TKI
Tony Mok, Pasi A Jänne, Makoto Nishio, et al.
Clinical Lung Cancer
|
July 13, 2024
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC
Martin Reck, Ernest Nadal, Nicolas Girard, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 8, 2017
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
Baohui Han, Sergei Tjulandin, Koichi Hagiwara, et al.
Translational Lung Cancer Research
|
August 25, 2021
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
Wolfgang M Brueckl, Martin Reck, Achim Rittmeyer, et al.
JTO Clinical and Research Reports
|
July 26, 2022
<b>Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Sta</b> <b>ge NSCLC With High Programmed Death-Ligand 1 Express</b> <b>ion</b>
Timothy Rajakumar, Rastislav Horos, Paul Kittner, et al.
Page
of 44
Search research articles
Search
Showing results (221-230 of 437) with videos related to
Sort By:
Page
of 44
Clinical Lung Cancer
|
January 11, 2018
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results
Martin Reck, Edward B Garon, Luis Paz-Ares, et al.
Clinical Lung Cancer
|
May 26, 2022
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer
Salma K Jabbour, Byoung Chul Cho, Emilio Bria, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)
Rathi N Pillai, Suresh S Ramalingam, Meena Thayu, et al.
NPJ Precision Oncology
|
December 8, 2021
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
Arlou Kristina Angeles, Petros Christopoulos, Zhao Yuan, et al.
Drug Safety
|
December 20, 2021
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
Ernest Nadal, Hidehito Horinouchi, Jin-Yuan Shih, et al.
Future Oncology (London, England)
|
December 14, 2023
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced <i>EGFR</i>-mutated NSCLC after a third-generation EGFR TKI
Tony Mok, Pasi A Jänne, Makoto Nishio, et al.
Clinical Lung Cancer
|
July 13, 2024
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC
Martin Reck, Ernest Nadal, Nicolas Girard, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 8, 2017
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
Baohui Han, Sergei Tjulandin, Koichi Hagiwara, et al.
Translational Lung Cancer Research
|
August 25, 2021
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
Wolfgang M Brueckl, Martin Reck, Achim Rittmeyer, et al.
JTO Clinical and Research Reports
|
July 26, 2022
<b>Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Sta</b> <b>ge NSCLC With High Programmed Death-Ligand 1 Express</b> <b>ion</b>
Timothy Rajakumar, Rastislav Horos, Paul Kittner, et al.
Page
of 44